Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:10 PM
Ignite Modification Date:
2025-12-24 @ 7:10 PM
NCT ID:
NCT04312503
Eligibility Criteria:
Inclusion Criteria:
* Patients with a diagnosis of schizophrenia according to DSM-5.
* Patients who gave their written consent for participation in the study and for personal data processing and willing to comply with all study procedures.
* Male and female patients ≥ of 18 years old at baseline.
* Patients treated or in treatment with any typical or atypical antipsychotic monotherapy or polytherapy.
* Patients switched from the pre-existing therapy to lurasidone, aripiprazole, olanzapine, quetiapine or risperidone in monotherapy within the preceding 2 weeks. The date of the switch is considered as baseline.
Exclusion Criteria:
* Female patients who are pregnant or lactating
* Patients fulfilling DSM-5 criteria for diagnosis of bipolar disorder and/or dementia.
* Amphetamines and/or Opiates abuse or dependence , as defined by DSM-5 criteria.
* Patients with no history of antipsychotics use.
* Patients recruited in another study as follows:
* currently enrolled in any pharmacological or non-pharmacological, interventional or observational study:
* who participated in the last 30 days to any observational or no-profit interventional study;
* who participated in the last 12 months to any interventional commercially sponsored study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04312503
Study Brief:
Protocol Section:
NCT04312503